Torcetrapib is a cholesterol ester transfer protein (CETP) inhibitor that exhibits anti-atherosclerotic and anti-diabetic activities. In vivo, this compound increases levels of HDL and glucose uptake and decreases levels of triglycerides, free fatty acids, blood glucose, and plasma insulin. Torcetrapib exhibits mixed results in clinical settings due to potential off-target actions on signaling pathways involving IL-2, PDGFR, and HGFR.
| Purity | ≥98% |
|---|---|
| Formula | C26H25F9N2O4 |
| Formula Wt. | 600.48 |
| Synonym | CP-529414 |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|
| Info Sheet | T5869 Info Sheet PDF |
|---|
Briand F, Prunet-Marcassus B, Thieblemont Q, et al. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters. Atherosclerosis. 2014 Apr;233(2):359-62. PMID: 24530763.
Fan S, Geng Q, Pan Z, et al. Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol. 2012 Dec 10;6:152. PMID: 23228038.
Johns DG, Duffy J, Fisher T, et al. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs. 2012 Mar 5;72(4):491-507. PMID: 22356288.
